Journal of Pharmacogenomics & Pharmacoproteomics

Therapeutic Response Monitoring: Measuring Treatment Effects for Safer and More Effective Care

Maria Oliveira ^* Department of Clinical Pharmacology, University of São Paulo, São Paulo, Brazil
^*Correspondence: Maria Oliveira, Department of Clinical Pharmacology, University of São Paulo, São Paulo, Brazil, Email:

Received: 29-Aug-2025 , Manuscript No. JPP-25-32619; Editor assigned: 01-Sep-2025 , Pre QC No. JPP-25-32619; Reviewed: 15-Sep-2025 , QC No. JPP-25-32619; Revised: 22-Sep-2025 , Manuscript No. JPP-25-32619; Published: 29-Sep-2025 , DOI: 10.35248/2153-0645.25.16.143

Description

Therapeutic response monitoring is a clinical approach used to assess how a patient responds to a medicine over time. It involves observing symptoms, laboratory measurements, molecular indicators, drug concentrations, imaging findings and other relevant clinical parameters. The main purpose is to determine whether a treatment is producing the intended effect, whether the dose is appropriate and whether unwanted effects are developing. Continuous assessment can support timely medication adjustments and help healthcare professionals make informed treatment decisions. Patients can respond differently to the same medicine because of variations in genetics, age, body composition, organ function, disease severity, metabolism, lifestyle and concurrent medications. A dose that produces an adequate response in one person may be insufficient or excessive in another. Therapeutic response monitoring provides a structured way to identify these differences during treatment rather than relying only on the initial prescription [1-3].

Clinical symptoms are among the simplest indicators used for monitoring treatment response. Changes in pain, blood pressure, blood glucose, breathing difficulty, fever, fatigue, or other disease-related symptoms can provide information about treatment effects. However, symptoms alone may not always provide sufficient information. Some medicines produce biological changes before noticeable symptoms improve, while other treatments may cause molecular changes without immediate clinical improvement. Laboratory measurements provide objective information about treatment effects. Blood glucose and glycated hemoglobin can be used when monitoring diabetes treatment, while lipid measurements can help assess responses to cholesterol-lowering medicines. Blood counts can provide information during treatments that affect bone marrow function. Liver and kidney measurements can also indicate whether a medicine is being tolerated adequately and whether dose adjustment may be required [4,5].

Therapeutic drug monitoring is particularly useful for medicines with a narrow concentration range between effective and harmful exposure. Measurements of drug concentrations in blood or plasma can help determine whether a patient is receiving an appropriate amount of medication. The interpretation of concentration depends on the timing of sample collection, dosage schedule, organ function, drug interactions and the established therapeutic range for the medicine. Pharmacokinetic monitoring examines how drug concentration changes within the body. Absorption, distribution, metabolism and elimination can vary substantially among patients. Kidney impairment, for example, can reduce the elimination of medicines that depend heavily on renal clearance. Liver dysfunction can affect the metabolism of several drugs. Monitoring drug levels alongside organ function can help healthcare professionals determine whether a dose needs modification [6,7].

Pharmacodynamic monitoring focuses on the biological effect produced by a medicine. Drug concentration and clinical effect do not always have a direct relationship. Two patients may have similar drug concentrations but experience different responses because of differences in receptor sensitivity, disease biology, signaling pathways, or other physiological factors. Monitoring pharmacodynamic indicators can provide additional information about whether a medicine is producing its intended biological effect. Molecular biomarkers can also contribute to therapeutic response monitoring. Changes in proteins, Ribonucleic Acid (RNA) molecules, metabolites, or genetic markers may reflect treatment activity. In oncology, molecular markers can be measured to assess whether tumor-related pathways are responding to therapy. In other diseases, changes in inflammatory proteins, hormone levels, or metabolic markers may provide information about treatment effects [8].

Imaging techniques can provide another form of response assessment. Radiological imaging may be used to evaluate changes in tumor size, organ structure, inflammation, or tissue function. Depending on the disease and treatment, imaging can be performed at defined intervals to determine whether the condition is improving, remaining stable, or progressing. Imaging results are generally interpreted together with clinical and laboratory information. Therapeutic response monitoring is especially important in cancer treatment. Anticancer medicines can produce different outcomes among patients with similar diagnoses. Monitoring may include physical assessment, blood tests, imaging, molecular biomarkers and symptom evaluation. Changes in tumor characteristics can indicate treatment effectiveness or the development of resistance. If the expected response is not observed, healthcare professionals may consider alternative treatment options [9,10].

Conclusion

In infectious diseases, response monitoring can involve body temperature, symptoms, microbial measurements, blood markers and antimicrobial susceptibility information. A decrease in pathogen levels or improvement in clinical symptoms may indicate effective treatment. Persistent infection despite appropriate medication can suggest inadequate drug exposure, resistance, poor adherence, or another underlying factor requiring further evaluation. Monitoring is also important for long-term therapies. Medicines used for cardiovascular disorders, autoimmune conditions, endocrine diseases, neurological conditions and other chronic illnesses may require periodic evaluation. Treatment goals can change as the patient's condition changes. Regular assessment can identify whether the current dose remains appropriate or whether another treatment strategy should be considered.

References

1. Reck M, Abreu RD, Robinson AG. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer . N Engl J Med. 2016;375(19):1823–1833.

   [Google Scholar] [Crossref] [PubMed]

2. Aje LF, Donoghue M, Chen H. FDA approval summary: Pembrolizumab for recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing PD-L1. Oncologist. 2019;24(1):103–109.

   [Google Scholar] [Crossref] [PubMed]

3. Peters S, Kerr KM, Stahel R. PD-1 blockade in advanced NSCLC: A focus on pembrolizumab. Cancer Treat Rev. 2018;62:39–49.

   [Google Scholar] [Crossref] [PubMed]

4. Pedoeem A, Alfaguter AI, Strazza M, Silverman GJ, Mor A. Programmed death-1 pathway in cancer and autoimmunity. Clin Immunol. 2014;153(1):145–152.

   [Google Scholar] [Crossref] [PubMed]

5. Diaz GA, Shin DS, Moreno BH. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 2017;19(6):1189–1201.

   [Google Scholar] [Crossref] [PubMed]

6. Mariathasan S, Turley SJ, Nickles D. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544–548.

   [Google Scholar] [Crossref] [PubMed]

7. Ahmadzadeh M, Johnson LA, Heemskerk B. Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood J Am Soc Hematol. 2009;114(8):1537–1544.

   [Google Scholar] [Crossref] [PubMed]

8. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Int J Surg. 2010;8(5):336–341.

   [Google Scholar] [Crossref] [PubMed]

9. Afsar B, Afsar RE, Bastani B, Rub FAA, Caliskan Y, Lentine KL, et al. Sodium intake estimation in chronic kidney disease: From measurement methods to clinical outcomes. Turk J Nephrol. 2025;34(3):160–168.

   [Google Scholar] [Crossref] [PubMed]

10. Lee PC, Ganguly S, Goh SY. Weight loss associated with sodium-glucose cotransporter-2 inhibition: A review of evidence and underlying mechanisms. Obes Rev. 2018;19(12):1630–1641.

    [Google Scholar] [Crossref] [PubMed]